Literature DB >> 21617213

Effect of hyperthermia on liver cell lines: important findings for thermal therapy in hepatocellular carcinoma.

Ursula Mayrhauser1, Philipp Stiegler, Vanessa Stadlbauer, Sonja Koestenbauer, Bettina Leber, Katja Konrad, Florian Iberer, Rupert Horst Portugaller, Karlheinz Tscheliessnigg.   

Abstract

BACKGROUND: Hepatocellular carcinoma is the fifth most common malignant tumour, with a high mortality rate. This study aimed to investigate the effect of hyperthermia on HepG2 and LX-1 cell lines to gain more information on thermal treatment of liver tumours.
MATERIALS AND METHODS: The cell lines HepG2, LX-1 and their co-cultures were heated from 55°C to 85°C for different time spans. After heat exposure, metabolic activity was measured immediately, and after 24 h and 48 h using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) test to assess how many cells had survived heating.
RESULTS: Our results show highly significant differences between the temperature tolerance of HepG2 and LX-1 cells. Alone, HepG2 cells are most sensitive to heat-induced cell death, their sensitivity decreased with rising percentages of LX-1 cells in the co-culture.
CONCLUSION: Our results suggest that the outcome of thermal cancer therapy is dependent on the temperature and the grade of fibrosis in the treated livers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617213

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Rickey E Carter; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  J Vasc Interv Radiol       Date:  2012-01-20       Impact factor: 3.464

2.  Clinical evaluation of in silico planning and real-time simulation of hepatic radiofrequency ablation (ClinicIMPPACT Trial).

Authors:  Michael Moche; Harald Busse; Jurgen J Futterer; Camila A Hinestrosa; Daniel Seider; Philipp Brandmaier; Marina Kolesnik; Sjoerd Jenniskens; Roberto Blanco Sequeiros; Gaber Komar; Mika Pollari; Martin Eibisberger; Horst Rupert Portugaller; Philip Voglreiter; Ronan Flanagan; Panchatcharam Mariappan; Martin Reinhardt
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

3.  Inhibition of mTOR promotes hyperthermia sensitivity in SMMC-7721 human hepatocellular carcinoma cell line.

Authors:  Qing-Liang Wang; B O Liu; Xiao-Jie Li; Kun-Peng Hu; Kun Zhao; Xiao-Ming Ye
Journal:  Exp Ther Med       Date:  2016-01-11       Impact factor: 2.447

4.  Synergistic Photothermal-Chemotherapy Based on the Use of Biomimetic Magnetic Nanoparticles.

Authors:  Ylenia Jabalera; Alberto Sola-Leyva; María P Carrasco-Jiménez; Guillermo R Iglesias; Concepcion Jimenez-Lopez
Journal:  Pharmaceutics       Date:  2021-04-28       Impact factor: 6.321

5.  Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.

Authors:  Gennaro Gadaleta-Caldarola; Stefania Infusino; Ida Galise; Girolamo Ranieri; Gianluca Vinciarelli; Vito Fazio; Rosa Divella; Antonella Daniele; Gianfranco Filippelli; Cosmo Damiano Gadaleta
Journal:  Oncol Lett       Date:  2014-07-24       Impact factor: 2.967

6.  Hydralazine augmented ultrasound hyperthermia for the treatment of hepatocellular carcinoma.

Authors:  Mrigendra B Karmacharya; Laith R Sultan; Stephen J Hunt; Chandra M Sehgal
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.